Whole-body MRI for lung cancer staging: a step in the right direction

Meyer, Mathias; Budjan, Johannes

doi:10.1016/s2213-2600(19)30081-5

Cited by 4 publications

(3 citation statements)

References 10 publications

(10 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The prompt diagnosis and staging of NSCLC provides vital information on the anatomical details and extent of cancer with respect to the size of the primary tumor, lymph nodal status, and the presence or absence of metastasis in distant organs, which can guide more assertive therapeutic decisions [ 30 , 31 ]. The National Comprehensive Cancer Network and European Society of Medical Oncology recommend an intravenous contrast agent-enhanced chest CT, 18-fluorodeoxyglucose ([18F]-FDG)-PET-CT and, depending on the guidelines, a brain MRI for staging of NSCLC before treatment with curative intent [ 32 , 33 , 34 ]. MRI was found to be typically used for diagnosis in most countries unless contraindications to this procedure exist.…”

Section: Discussionmentioning

confidence: 99%

Real-World Journey of Unresectable Stage III NSCLC Patients: Current Dilemmas for Disease Staging and Treatment

Agbarya

Shalata

Addeo

et al. 2022

JCM

View full text Add to dashboard Cite

Daily-practice challenges in oncology have been intensified by the approval of immune checkpoint inhibitors (ICI). We aimed to outline current therapy policies and management of locally advanced unresectable stage III non-small-cell lung cancer (NSCLC) in different countries. One thoracic oncologist from each of the following countries—Belgium, Croatia, Greece, Israel, the Netherlands, Norway, Poland, Portugal, Romania, Slovenia, and Switzerland—participated in an electronic survey. Descriptive statistics were conducted with categorical variables reported as frequencies and continuous variables as median and interquartile range (IQR) (StataSE-v15). EBUS (endobronchial ultrasound bronchoscopy) was used either upfront or for N2 confirmation. Resectability is still a source of disagreement; thus, decisions vary within each multidisciplinary team. Overall, 66% of stage III patients [IQR 60–75] undergo chemoradiation therapy (CRT); concurrent CRT (cCRT) accounts for most cases (~70%). Performance status is universally used for cCRT eligibility. Induction chemotherapy is fairly weighted based on radiotherapy (RT) availability. Mean time to evaluation after RT completion is less than a month; ICI consolidation is started within six weeks. Durvamulab expenditures are reimbursed in all countries, yet some limiting criteria exist (PD-L1 ≥ 1%, cCRT). No clear guidance on therapies at Durvamulab progression exist; experts agree that it depends on progression timing. Given the high heterogeneity in real-world practices, standardized evidence-based decisions and healthcare provision in NSCLC are needed.

show abstract

Section: Discussionmentioning

confidence: 99%

Real-World Journey of Unresectable Stage III NSCLC Patients: Current Dilemmas for Disease Staging and Treatment

Agbarya

Shalata

Addeo

et al. 2022

JCM

View full text Add to dashboard Cite

show abstract

“…Several radiological screening techniques, including chest x-ray, computed tomography (CT) scan of the chest and thorax, bronchoscopy, ultrasound of the chest and lungs, magnetic resonance imaging (MRI), and positron emission tomography (PET), have been used to aid the diagnosis of lung cancer in HIC countries, through the detection of suspicious lesions and sampling of mediastinal lymph nodes [21][22][23][24][25]. Lung biopsies are obtained by bronchoscopy and surgical procedures for histopathological analysis and appraisal.…”

Section: Introductionmentioning

confidence: 99%

Molecular Epidemiology and Histopathological Classifications of Lung Cancer in Africa: A Scoping Review Protocol

Asiamah

Hlongwa

Nyamande

et al. 2022

Preprint

View full text Add to dashboard Cite

Introduction: Lung cancer is a leading cause of death globally and an emerging epidemic in Africa. Recent advances in molecular biomarkers and understanding of the cancer epidemiology and population-based genomic profile for early detection, diagnosis and treatment show promise in reducing incidence and mortality rate. However, this is lacking in Africa. The main objective of this scoping review is to map the evidence on lung cancer molecular epidemiology, genomic profile, and histopathological distributions in Africa. Methods and analysis: This review will be guided by Arksey and O'Malley's framework and Levac et al.'s recommendation for methodological enhancement for scoping review studies. A search for keywords from scientific databases (PubMed/MEDLINE, EBSCOhost, SCOPUS and Google Scholar) and grey literature will be conducted for evidence on the molecular epidemiology and histopathological classifications of lung cancer in Africa. The Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA)-Scoping Review Extension guidelines will be used to report screened results. We will use the PRISMA-ScR checklist to ensure the study adheres to sound methodological rigour acceptable for scoping reviews. The study's search strategy will include Boolean terms ('AND' and 'OR') and Medical Subject Heading (MeSH) terms. Ethics and dissemination: This review will not include animal or human participants. Ethics approval and consent to participate are not applicable. Findings of this scoping review will be disseminated via electronic/social media, conferences, meetings with stakeholders and peer-review publications. Keywords: Lung cancer epidemiology, histopathological classifications, early detection, molecular biomarkers, Africa. Strengths and limitations of the study ► This review will be the first to identify and map evidence that assesses the molecular epidemiological diversity and histopathological distributions of lung cancer in Africa. ► The summary of evidence obtained from relevant studies in the African context will help understand the genetic diversity of lung cancer among high-risk heterogenous African populations and guide future research towards early detection and targeted therapy in the African context. ► The review will include all available studies in the literature with no time or language restrictions. Thus, studies published in languages apart from English will be translated using an online tool. ► There will be no quality appraisal of the included studies.

show abstract

“…Incomplete resection is complete tumor resection under the naked eye, but there are still residues under the light microscope. Complete resection is the complete tumor resection under the naked eye, and there is no residue under the light microscope [5]. Studies reported that the 5-year survival rate of patients with early lung cancer after surgical treatment was 45-65% and that of patients with advanced lung cancer after nonsurgical treatment was 5-10% [6][7][8].…”

Section: Introductionmentioning

confidence: 99%

Magnetic Resonance Imaging Segmentation on the Basis of Boundary Tracking Algorithm in Lung Cancer Surgery

Liu

Yikai

et al. 2021

Contrast Media & Molecular Imaging

View full text Add to dashboard Cite

This work was to study the guiding value of magnetic resonance imaging (MRI) based on the target region boundary tracking algorithm in lung cancer surgery. In this study, the traditional boundary tracking algorithm was optimized, and the target neighborhood point boundary tracking method was proposed. The iterative method was used to binarize the lung MRI image, which was applied to the MRI images of 50 lung cancer patients in hospital. The patients were divided into two groups as the progression-free survival (PFS) and overall survival (OS) of surgical treatment group (experimental group, n = 25) and nonsurgical treatment group (control group, n = 25). The experimental group received surgical resection, while the control group received systemic chemotherapy. The results showed that the traditional boundary tracking algorithm needed to manually rejudge whether the concave and convex parts of the image were missing. The target boundary tracking algorithm can effectively avoid the leakage of concave and convex parts and accurately locate the target image contour, fast operation, without manual intervention. The PFS time of the experimental group (325 days) was significantly higher than that of the control group (186 days) P < 0.05 . The OS time of the experimental group (697 days) was significantly higher than that of the control group (428 days) P < 0.05 . Fisher exact probability method was used to test the total survival time of patients in the two groups, and the tumor classification and treatment group had significant influence on the OS time P < 0.05 . The target boundary tracking algorithm in this study can effectively locate the contour of the target image, and the operation speed was fast. Surgical resection of lung cancer can improve the PFS and OS of patients.

show abstract

Whole-body MRI for lung cancer staging: a step in the right direction

Cited by 4 publications

References 10 publications

Real-World Journey of Unresectable Stage III NSCLC Patients: Current Dilemmas for Disease Staging and Treatment

Real-World Journey of Unresectable Stage III NSCLC Patients: Current Dilemmas for Disease Staging and Treatment

Molecular Epidemiology and Histopathological Classifications of Lung Cancer in Africa: A Scoping Review Protocol

Magnetic Resonance Imaging Segmentation on the Basis of Boundary Tracking Algorithm in Lung Cancer Surgery

Contact Info

Product

Resources

About